SS Innovations International, a developer of surgical robotic technologies, has completed a private placement of common stock, generating approximately $18.6 million in gross proceeds. The financing includes participation from insiders and existing shareholders, with funds earmarked for working capital and global expansion efforts.
Key takeaways
- The offering comprised 5,774,839 shares, with insider purchases from CEO Dr. Sudhir Srivastava, Vice-Chairman Dr. Frederic H. Moll, and Director Tim Adams totaling about $5.2 million at $4 per share.
- An additional 4,474,833 shares were sold at $3 per share, raising approximately $13.4 million from existing and new investors, led by Manipal Global Health Services.
- Proceeds will support growth in India and other markets, and preparation for entry into the U.S. and EU.
- The company anticipates FDA review of its 510(k) for the SSi Mantra system by mid-2026, with CE marking expected later in the year.
This capital infusion underscores investor confidence in SS Innovations' strategy to democratize access to surgical robotics, with a clear regulatory pathway ahead.
Source: Robotics & Automation News (roboticsandautomationnews.com) · Published 2026-03-10 · “SS Innovations completes $18.6 million private placement to support growth initiatives”